Health Canada Approves Sevmia, the First Generic Semaglutide for Weight Management

On June 29, 2026, Health Canada approved Sevmia (semaglutide injection), manufactured by Apotex, as the first generic semaglutide product authorized in Canada specifically for chronic weight management in patients 12 years of age and older, as a supplement to a reduced-calorie diet and increased physical activity. Sevmia references the brand-name product Wegovy. This follows Canada becoming, on April 28, 2026, the first G7 country to approve a generic version of semaglutide at all — that earlier approval, and a second one from Apotex on May 1, 2026, were both authorized for the type 2 diabetes indication carried by Ozempic. Sevmia is a distinct, third generic authorization tied to the weight-management indication and dosing range instead.

Why the distinction matters

Semaglutide is marketed in Canada under different brand names and dose ranges depending on indication — Ozempic for type 2 diabetes and Wegovy for chronic weight management — and generic manufacturers must seek separate authorization referencing the specific brand and indication they are copying. A generic approved against the diabetes-indicated reference product is not automatically interchangeable with, or approved for, the weight-management indication and dose titration schedule, and vice versa. Health Canada says it is reviewing several more generic semaglutide submissions, so pharmacists should expect this brand-and-indication distinction to come up repeatedly as additional products reach the market over the coming months.

Practice guidance for pharmacists

• Verify which reference product and indication a given generic semaglutide is authorized against before substituting, rather than assuming any semaglutide generic is interchangeable with any brand.
• Check current provincial formulary and interchangeability listings before dispensing Sevmia or any other generic semaglutide, since listing and reimbursement status can lag behind Health Canada approval.
• Counsel patients switching from brand-name Wegovy to Sevmia on injection device differences, since generic injectable devices are not guaranteed to match the brand pen's mechanics or dose-dialing steps.
• Confirm the patient's indication and dosing schedule match the product's approved use — weight-management dosing for semaglutide differs materially from the diabetes dosing range.
• Watch for updates as Health Canada completes review of the remaining generic semaglutide submissions, since further approvals may affect supply and substitution options in a drug class that has faced recurrent shortages.

The arrival of generic competition is expected to ease both cost and supply pressure in a drug class that has seen persistent shortages driven by surging demand, and Health Canada has noted that generic medications are typically 45 to 90 percent cheaper than their brand-name equivalents. Pharmacists should expect ongoing changes to the semaglutide generic landscape as more submissions clear review.